AP
Therapeutic Areas
Mersana Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Upifitamab rilsodotin (UpRi) | Platinum-Resistant Ovarian Cancer | Phase 3 |
| XMT-1660 | Breast Cancer (e.g., HR+/HER2-) | Phase 1 |
| XMT-2056 | Advanced/Recurrent Solid Tumors (HER2+) | Phase 1 |
| XMT-1592 | NSCLC (NaPi2b-expressing) | Phase 1 |
Leadership Team at Mersana Therapeutics
MH
Martin Huber, M.D.
President and Chief Executive Officer
BD
Brian DeSchuytner
Senior Vice President, Chief Financial Officer
TB
Timothy B. Lowinger, Ph.D.
Chief Science and Technology Officer
AY
Arvin Yang, M.D., Ph.D.
Chief Medical Officer